T
Tamás Pintér
Researcher at Groote Schuur Hospital
Publications - 58
Citations - 11590
Tamás Pintér is an academic researcher from Groote Schuur Hospital. The author has contributed to research in topics: Docetaxel & Breast cancer. The author has an hindex of 23, co-authored 57 publications receiving 10627 citations.
Papers
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis J. Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martin,Michael F. Press,John R. Mackey,John A. Glaspy,Arlene Chan,M. Pawlicki,Tamás Pintér,Vicente Valero,Mei Ching Liu,Guido Sauter,Gunter von Minckwitz,Frances M. Visco,Valerie Bee,Marc Buyse,Belguendouz Bendahmane,Isabelle Tabah-Fisch,Mary Ann Lindsay,Alessandro Riva,John Crown +22 more
TL;DR: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer and the risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.
Journal ArticleDOI
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
Journal ArticleDOI
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin,Tadeusz Pienkowski,John R. Mackey,M. Pawlicki,Jean-Paul Guastalla,Charles Weaver,Eva Tomiak,T. Al-Tweigeri,Linnea Chap,Eva Juhos,Raymond Guevin,Anthony Howell,Tommy Fornander,John D. Hainsworth,Robert E. Coleman,Jefferson Vinholes,Manuel Modiano,Tamás Pintér,Shou C. Tang,Bruce Colwell,Catherine Prady,Louise Provencher,David Walde,Álvaro Rodríguez-Lescure,Judith Hugh,Camille Loret,Matthieu Rupin,Sandra Blitz,Philip Jacobs,Michael Murawsky,Alessandro Riva,Charles L. Vogel +31 more
TL;DR: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.
Journal ArticleDOI
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Stephen Chan,K. Friedrichs,Daniel Noel,Tamás Pintér,Simon Van Belle,Daniel A. Vorobiof,Ricardo Duarte,M. Gil,Istvan Bodrogi,Elizabeth Murray,Louise Yelle,Gunter von Minckwitz,Stefan Korec,Peter Simmonds,Franco Buzzi,Rosario González Mancha,Gary Richardson,Euan Walpole,Monica Ronzoni,Michael Murawsky,May Alakl,Alessandro Riva,John Crown +22 more
TL;DR: The observed differences in activity and toxicity profiles provide a basis for therapy choice and confirms the rationale for combination studies in early breast cancer.